Cart
sales@molnova.com
NEO2734
CAS No. 2081072-29-7
NEO2734( EP31670 )
Catalog No. M22391 CAS No. 2081072-29-7
NEO2734 is an orally active and selective inhibitor of p300/CBP and BET bromodomain(IC50 of <30 nM for both p300/CBP and BET bromodomains).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 260 | In Stock |
|
| 10MG | 430 | In Stock |
|
| 25MG | 710 | In Stock |
|
| 50MG | 972 | In Stock |
|
| 100MG | 1332 | In Stock |
|
| 500MG | 2673 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNEO2734
-
NoteResearch use only, not for human use.
-
Brief DescriptionNEO2734 is an orally active and selective inhibitor of p300/CBP and BET bromodomain(IC50 of <30 nM for both p300/CBP and BET bromodomains).
-
DescriptionNEO2734 is an orally active and selective inhibitor of p300/CBP and BET bromodomain(IC50 of <30 nM for both p300/CBP and BET bromodomains).NEO2734, a novel dual inhibitor of BET and CBP/p300, is active in both hotspot mutant (F133V) and non-hotspot mutant (Q165P) PCa cells in vitro and in vivo.
-
In VitroWestern Blot Analysis Cell Line:NUT carcinoma patient cell lines (TC-797 and PER-403).Concentration:1 μM.Incubation Time:6 h.Result:Results in greater loss of MYC protein.
-
In VivoAnimal Model:Mice (PER-403 and 14169 models).Dosage:5, 8, 10 mg/kg Administration:Orally, once daily for 28 days.Result:Two of the three mice treated with NEO2734 were alive by day 100.Provided markedly improved survival compared with EP, i-BET-762, and even iBET-762+EP by day 100 following initiation of treatment.
-
SynonymsEP31670
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
Recptorp300/CBP|BET bromodomain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2081072-29-7
-
Formula Weight435.44
-
Molecular FormulaC22H24F3N3O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (229.65 mM)
-
SMILESCc1cc(cn(C)c1=O)-c1ccc2nc(C3CCOCC3)n(CCOC(F)(F)F)c2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
molnova catalog
related products
-
SGC-SMARCA-BRDVIII
SGC-SMARCA-BRDVIII is a potent and selective inhibitor of SMARCA2, SMARCA4, PB1(2), PB1(3) and PB1(5) with Kds of 35 nM, 36 nM, 3.7 μM, 2.0 μM and 13 nM, respectively.
-
UMB298
UMB298 is a potent and selective CBP/P300 bromodomain inhibitor. UMB298 inhibits BRD4 with IC50 of 5193nM.
-
Y06036
Y06036 a potent and selective BET inhibitor can bind to the BRD4(1) bromodomain (Kd: 82 nM).
